九強生物(300406.SZ):8項產品取得醫療器械註冊證
格隆匯2月15日丨九強生物(300406.SZ)公佈,2023年2月15日,公司收到北京市藥品監督管理局頒發的8項《醫療器械註冊證》,產品名稱分別為“鋰測定試劑盒(類卟啉顯色法)”、“甘油三酯測定試劑盒(GPO-PAP法)”、“纖維蛋白原測定試劑盒(免疫比濁法)”、“降鈣素原測定試劑盒(磁微粒化學發光法)”、“抗凝血酶III(ATIII)校準品”、“鋅測定試劑盒(PAPS顯色劑法)”、“地高辛測定試劑盒(均相酶免疫法)”及“抗凝血酶III(ATIII)質控品”。
上述產品醫療器械註冊證的取得,豐富了公司產品類別,其中“鋅測定試劑盒(PAPS顯色劑法)”為配套羅氏儀器封閉通道專用試劑。取得醫療器械註冊證有利於增強公司的核心競爭力,對公司未來發展具有正面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.